Beyond Sponsors: This same expertise extends to clinical-trial technology vendors, UAT and end-user workflow validation for recruitment, retention, forecasting, and analytics reporting platforms, informed by real practitioner experience. Additionally, it applies to site networks building the enrollment and performance benchmarking story they want to bring to sponsors.


A feasibility process that isn’t well understood from the inside is hard to trust and hard to improve — whether you’re at a major pharma with dedicated infrastructure or a lean emerging biotech building it as you go. When you don’t know what good looks like, you can’t evaluate what you’re receiving, or know what you’re missing.

I’ve seen this play out on both sides: teams receiving CRO forecasts with no real transparency into the data or methodology behind them, and teams generating deliverables in-house without a clear framework for what they should contain. Either way, you end up with a plan you can’t fully defend.

With 13+ years across major pharma, emerging biotech, CROs, and vendors — and deep experience as a key member of clinical development teams — I know what rigorous feasibility, forecasting, and metrics strategy looks like, and where it breaks down. I bring particular depth in immune-mediated indications, including dermatology, rheumatology, and rare disease, with experience spanning oncology, CNS, and beyond.

I started Walters Clinical Advisory so that teams can treat feasibility as a foundation, not a formality — and move forward with real confidence in the data and the plan behind it.

Tana Walters, Founder